Evidence map›Paper›PMID 28317317›Full record

ReviewCNS neuroscience & therapeutics2017

The neuroprotective effects of caffeine in neurodegenerative diseases.

Mahshad Kolahdouzan, Mazen J Hamadeh

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS neuroscience & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 4 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 4 syntheses or guidelines pooled it, 297 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Association between caffeine intake and fat free mass index: a retrospective cohort study.Journal of the International Society of Sports Nutrition · 2025
    Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mahshad KolahdouzanSchool of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.
Mazen J HamadehSchool of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-3511-4345
York University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Caffeine is the most widely used psychostimulant in Western countries, with antioxidant, anti-inflammatory and anti-apoptotic properties. In Alzheimer's disease (AD), caffeine is beneficial in both men and women, in humans and animals. Similar effects of caffeine were observed in men with Parkinson's disease (PD); however, the effect of caffeine in female PD patients is controversial due to caffeine's competition with estrogen for the estrogen-metabolizing enzyme, CYP1A2. Studies conducted in animal models of amyotrophic lateral sclerosis (ALS) showed protective effects of A

Indexed as

AnimalsCaffeineHumansNeurodegenerative DiseasesNeuroprotective AgentsCaffeineNeuroprotective Agentsadenosine receptorAlzheimer diseaseamyotrophic lateral sclerosiscaffeinedosageHuntington diseaseneurodegenerative diseaseneuroprotectionParkinson disease

Identifiers

PMID28317317
PMCPMC6492672
OpenAlexW2601931132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.